Immune-related adverse effects of immune checkpoint inhibitor therapy


  • An extensive diagnostic workup that incorporates magnetic resonance imaging (MRI), pathology tests, and cerebrospinal fluid (CSF) analyses is required to differentiate between immune-related adverse events (irAEs) and other differential diagnoses in patients undergoing cancer immunotherapy.

Why this matters

  • Immune checkpoint inhibitors have been very effective for treating melanoma. However, irAEs can be severe and require early diagnosis and treatment.

  • Although neurotoxicity is rare in patients following immune checkpoint inhibitor and BRAF/MEK inhibitor treatments, there is the possibility that a cumulative effect of these treatments may be associated with the pathophysiology of neurological adverse effects.

International Medical Press is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, International Medical Press recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of International Medical Press or the sponsor. International Medical Press assumes no liability for any material contained herein.